Follow The Filings

MYGN Myriad Genetics

Myriad Genetics earnings company data as of 9:00 AM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 4 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by MYGN's executives, directors and 10% owners in the last 12 months, from their Form 4s

All MYGN insider trades
  • $722K bought by 3 insiders
  • None no sales outside a trading plan
  • $67K sold by 1 insider under 10b5-1 plans
  1. Rashmi Kumar Director
    Planned sale
    $67K 15,000 shares at $4.46 8% of stake
    Traded Jun 8 Filed Jun 9
    ↗
  2. Paul Bisaro Director
    Buy
    $28K 7,500 shares at $3.69 +8.3% to stake
    Traded May 14 Filed May 14
    ↗
  3. Samraat S. Raha CEO
    Buy
    $200K 40,000 shares at $5.00 +8.8% to stake
    Traded Mar 9 Filed Mar 9
    ↗
  4. S. Louise Phanstiel Director
    Buy
    $495K 104,507 shares at $4.73 +59% to stake
    Traded Feb 25–27 Filed Feb 27
    ↗

Also filed in the last 12 months, not counted as buying or selling: 34 share withholdings for taxes and 23 stock grants.

SEC filings

Recent issuer filings from EDGAR, 18 shown.

Filed Form Detail Links
8-K 1.01,7.01,9.01 Filing Doc
8-K 5.02,9.01 Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.02 Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 3 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.